What is Concord Medical's earnings per share (EPS)?

Concord Medical (CCM) reported diluted earnings per share of $-0.10 for fiscal year 2025. This represents a 68.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Concord Medical Financials

CCM

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Concord Medical (CCM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CCM FY2024 2026-04-29

External financing is carrying a business whose core services remain loss-making and whose cash burn outruns internal liquidity.

From FY2022 through FY2024, gross profit stayed negative while operating cash flow also stayed negative, which means losses are not mainly a head-office or accounting issue; the underlying service activity itself has not covered direct delivery costs, and the cash statements confirm that shortfall is economically real. FY2024 then added $26.5M of interest expense against only $52.6M of revenue, so the financing structure is absorbing a large share of a business that is already underwater before corporate overhead.

The balance sheet has become refinancing-dependent: the current ratio slid from 1.3x to 0.5x over the period. Equity was still negative at -$312.4M, so near-term obligations are not backed by either liquid assets or an equity cushion.

FY2024 cash did not improve because operations funded themselves; financing inflows of $157.0M outweighed the year’s operating and investing outflows. With free cash flow at -$75.1M, reinvestment is still an added use of cash rather than a self-funded maintenance cycle.

Financial Health Signals

Financial Profile 17/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Concord Medical's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Concord Medical has an operating margin of -56.8%, meaning the company retains $-57 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -138.6% the prior year.

Growth

Concord Medical's revenue surged 25.2% year-over-year to $65.9M, reflecting rapid business expansion. This strong growth earns a score of 22/100.

Leverage

Concord Medical carries a low D/E ratio of -1.17, meaning only $-1.17 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 79/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Concord Medical's current ratio of 0.48 is below the typical benchmark, resulting in a score of 4/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

While Concord Medical generated -$28.9M in operating cash flow, capex of $8.1M consumed most of it, leaving -$36.9M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Neutral

5/9

Concord Medical passes 5 of 9 financial strength tests. 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

2.17x

For every $1 of reported earnings, Concord Medical generates $2.17 in operating cash flow (-$28.9M OCF vs -$13.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-1.7x

Concord Medical earns $-1.7 in operating income for every $1 of interest expense (-$37.4M vs $21.8M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$65.9M

YoY+25.2%

5Y CAGR+14.0%

10Y CAGR-3.6%

Concord Medical generated $65.9M in revenue in fiscal year 2025. This represents an increase of 25.2% from the prior year.

EBITDA

-$16.1M

YoY+70.8%

Concord Medical's EBITDA was -$16.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 70.8% from the prior year.

Net Income

-$13.3M

YoY+68.6%

Concord Medical reported -$13.3M in net income in fiscal year 2025. This represents an increase of 68.6% from the prior year.

EPS (Diluted)

$-0.10

YoY+68.8%

Concord Medical earned $-0.10 per diluted share (EPS) in fiscal year 2025. This represents an increase of 68.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$36.9M

YoY+50.9%

Concord Medical generated -$36.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 50.9% from the prior year.

Cash & Debt

$42.6M

YoY+43.7%

5Y CAGR-3.6%

10Y CAGR-4.8%

Concord Medical held $42.6M in cash against $352.6M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

130M

5Y CAGR+0.0%

10Y CAGR-0.2%

Concord Medical had 130M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

5.6%

YoY+26.2pp

5Y CAGR-0.3pp

10Y CAGR-37.1pp

Concord Medical's gross margin was 5.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 26.2 percentage points from the prior year.

Operating Margin

-56.8%

YoY+81.8pp

5Y CAGR+84.9pp

10Y CAGR-55.9pp

Concord Medical's operating margin was -56.8% in fiscal year 2025, reflecting core business profitability. This is up 81.8 percentage points from the prior year.

Net Margin

-20.2%

YoY+60.1pp

5Y CAGR+118.9pp

10Y CAGR-7.5pp

Concord Medical's net profit margin was -20.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 60.1 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

$20.0M

10Y CAGR+20.7%

Concord Medical spent $20.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$8.1M

YoY-61.0%

5Y CAGR-20.7%

10Y CAGR+0.9%

Concord Medical invested $8.1M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 61.0% from the prior year.

CCM Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$65.9M+25.2%	$52.6M-30.5%	$75.7M+10.6%	$68.4M-10.2%	$76.2M+123.0%	$34.2M
Cost of Revenue	$62.2M-2.0%	$63.4M-26.6%	$86.5M-4.5%	$90.5M+6.4%	$85.1M+164.6%	$32.2M
Gross Profit	$3.7M+134.0%	-$10.8M-0.5%	-$10.8M+51.2%	-$22.1M-147.5%	-$8.9M-545.3%	$2.0M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$30.5M-45.0%	$55.4M+19.2%	$46.5M+3.1%	$45.1M-17.3%	$54.6M+20.8%	$45.2M
Operating Income	-$37.4M+48.7%	-$72.9M-11.8%	-$65.2M+14.3%	-$76.1M-5.8%	-$71.9M-48.5%	-$48.4M
Interest Expense	$21.8M-17.7%	$26.5M+13.4%	$23.3M+33.7%	$17.4M+50.7%	$11.6M-7.1%	$12.5M
Income Tax	$867K+136.2%	-$2.4M+30.7%	-$3.5M+66.3%	-$10.3M-898.1%	-$1.0M+82.1%	-$5.8M
Net Income	-$13.3M+68.6%	-$42.2M-0.7%	-$41.9M+40.9%	-$71.0M-66.7%	-$42.6M+10.3%	-$47.5M
EPS (Diluted)	$-0.10+68.8%	$-0.320.0%	$-0.32+40.7%	$-0.54	N/A	N/A

Metric	Q4'25	Q4'24	Q4'23	Q4'22	Q4'21	Q4'20	Q4'19	Q4'18
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CCM Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$936.3M+1.6%	$921.5M+8.1%	$852.7M-2.1%	$870.6M-10.9%	$977.6M+19.6%	$817.6M
Current Assets	$134.7M-0.1%	$134.8M+55.1%	$86.9M-21.1%	$110.2M+20.1%	$91.7M-11.5%	$103.6M
Cash & Equivalents	$42.6M+43.7%	$29.6M+261.7%	$8.2M-64.3%	$22.9M-7.1%	$24.7M-51.8%	$51.2M
Inventory	$6.6M+43.5%	$4.6M-19.4%	$5.7M-53.8%	$12.3M+105.8%	$6.0M+80.4%	$3.3M
Accounts Receivable	$6.3M-10.1%	$7.0M-32.3%	$10.4M-45.2%	$18.9M-5.9%	$20.1M+69.3%	$11.9M
Goodwill	$81.8M0.0%	$81.8M+3.8%	$78.8M-2.7%	$81.0M-3.9%	$84.4M+151.6%	$33.5M
Total Liabilities	$1.2B+0.2%	$1.2B+7.2%	$1.2B+0.9%	$1.1B-4.3%	$1.2B+29.8%	$919.2M
Current Liabilities	$279.5M-4.0%	$291.2M+5.9%	$274.8M+69.1%	$162.6M+28.8%	$126.2M+60.8%	$78.5M
Long-Term Debt	$352.6M-4.5%	$369.0M+31.4%	$280.9M-21.6%	$358.3M+4.8%	$341.9M+13.3%	$301.6M
Total Equity	-$300.7M+3.7%	-$312.4M-4.5%	-$298.9M-10.6%	-$270.3M-25.7%	-$215.0M-111.6%	-$101.6M
Retained Earnings	-$638.6M-6.6%	-$599.1M-4.6%	-$572.5M-4.8%	-$546.2M-6.2%	-$514.3M-36.6%	-$376.5M

Metric	Q4'25	Q4'24	Q4'23	Q4'22	Q4'21	Q4'20	Q4'19	Q4'18
Total Assets	$936.3M+1.6%	$921.5M+8.1%	$852.7M-2.1%	$870.6M-10.9%	$977.6M+19.6%	$817.6M+32.4%	$617.3M-7.4%	$666.9M
Current Assets	$134.7M-0.1%	$134.8M+55.1%	$86.9M-21.1%	$110.2M+20.1%	$91.7M-11.5%	$103.6M+155.3%	$40.6M-77.3%	$178.7M
Cash & Equivalents	$42.6M+43.7%	$29.6M+261.7%	$8.2M-64.3%	$22.9M-7.1%	$24.7M-51.8%	$51.2M+379.9%	$10.7M-81.9%	$58.9M
Inventory	$6.6M+43.5%	$4.6M-19.4%	$5.7M-53.8%	$12.3M+105.8%	$6.0M+80.4%	$3.3M+430.8%	$624K+27.9%	$488K
Accounts Receivable	$6.3M-10.1%	$7.0M-32.3%	$10.4M-45.2%	$18.9M-5.9%	$20.1M+69.3%	$11.9M+12.0%	$10.6M-16.2%	$12.6M
Goodwill	$81.8M0.0%	$81.8M+3.8%	$78.8M-2.7%	$81.0M-3.9%	$84.4M+151.6%	$33.5M+4.0%	$32.3M+35.9%	$23.7M
Total Liabilities	$1.2B+0.2%	$1.2B+7.2%	$1.2B+0.9%	$1.1B-4.3%	$1.2B+29.8%	$919.2M+44.8%	$634.9M+5.2%	$603.3M
Current Liabilities	$279.5M-4.0%	$291.2M+5.9%	$274.8M+69.1%	$162.6M+28.8%	$126.2M+60.8%	$78.5M-12.9%	$90.1M-28.8%	$126.6M
Long-Term Debt	$352.6M-4.5%	$369.0M+31.4%	$280.9M-21.6%	$358.3M+4.8%	$341.9M+13.3%	$301.6M+62.6%	$185.6M+156.4%	$72.4M
Total Equity	-$300.7M+3.7%	-$312.4M-4.5%	-$298.9M-10.6%	-$270.3M-25.7%	-$215.0M-111.6%	-$101.6M-476.2%	-$17.6M-127.7%	$63.6M
Retained Earnings	-$638.6M-6.6%	-$599.1M-4.6%	-$572.5M-4.8%	-$546.2M-6.2%	-$514.3M-36.6%	-$376.5M-46.8%	-$256.5M-43.0%	-$179.3M

CCM Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$28.9M+47.0%	-$54.5M-39.9%	-$38.9M-24.0%	-$31.4M+44.3%	-$56.4M-60.1%	-$35.2M
Capital Expenditures	$8.1M-61.0%	$20.7M+29.8%	$15.9M-50.8%	$32.3M-26.2%	$43.8M+70.0%	$25.8M
Free Cash Flow	-$36.9M+50.9%	-$75.1M-37.0%	-$54.9M+13.9%	-$63.7M+36.4%	-$100.2M-64.3%	-$61.0M
Investing Cash Flow	$7.7M+109.5%	-$81.3M-1110.7%	-$6.7M+61.0%	-$17.2M+80.6%	-$88.8M-8.5%	-$81.8M
Financing Cash Flow	$28.2M-82.0%	$157.0M+332.6%	$36.3M-34.7%	$55.5M-44.9%	$100.8M-42.2%	$174.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$20.0M	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q4'24	Q4'23	Q4'22	Q4'21	Q4'20	Q4'19	Q4'18
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CCM Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	5.6%+26.2pp	-20.6%-6.4pp	-14.3%+18.0pp	-32.3%-20.6pp	-11.7%-17.6pp	5.9%
Operating Margin	-56.8%+81.8pp	-138.6%-52.4pp	-86.2%+25.1pp	-111.2%-16.8pp	-94.4%+47.3pp	-141.7%
Net Margin	-20.2%+60.1pp	-80.3%-24.9pp	-55.4%+48.3pp	-103.7%-47.8pp	-55.9%+83.1pp	-139.0%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-1.4%+3.2pp	-4.6%+0.3pp	-4.9%+3.2pp	-8.2%-3.8pp	-4.4%+1.4pp	-5.8%
Current Ratio	0.48+0.0	0.46+0.1	0.32-0.4	0.68-0.0	0.73-0.6	1.32
Debt-to-Equity	-1.170.0	-1.18-0.2	-0.94+0.4	-1.33+0.3	-1.59+1.4	-2.97
FCF Margin	-56.1%+86.8pp	-142.9%-70.4pp	-72.5%+20.7pp	-93.1%+38.3pp	-131.4%+46.9pp	-178.4%

Metric	Q4'25	Q4'24	Q4'23	Q4'22	Q4'21	Q4'20	Q4'19	Q4'18
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	0.48+0.0	0.46+0.1	0.32-0.4	0.68-0.0	0.73-0.6	1.32+0.9	0.45-1.0	1.41
Debt-to-Equity	-1.170.0	-1.18-0.2	-0.94+0.4	-1.33+0.3	-1.59+1.4	-2.97+7.6	-10.52-11.7	1.14
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$300.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.48), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Basel Medical Group Ltd BMGL

$12.3M

Amer Shared Hosp AMS

$9.7M

Cryo-Cell Intl Inc CCEL

$29.2M

Modivcare Inc MODV

$6.2M

NewGenIvf Group NIVF

$512K

Frequently Asked Questions

What is Concord Medical's annual revenue?

Concord Medical (CCM) reported $65.9M in total revenue for fiscal year 2025. This represents a 25.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Concord Medical's revenue growing?

Concord Medical (CCM) revenue grew by 25.2% year-over-year, from $52.6M to $65.9M in fiscal year 2025.

Is Concord Medical profitable?

No, Concord Medical (CCM) reported a net income of -$13.3M in fiscal year 2025, with a net profit margin of -20.2%.

What is Concord Medical's EBITDA?

Concord Medical (CCM) had EBITDA of -$16.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Concord Medical have?

As of fiscal year 2025, Concord Medical (CCM) had $42.6M in cash and equivalents against $352.6M in long-term debt.

What is Concord Medical's gross margin?

Concord Medical (CCM) had a gross margin of 5.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Concord Medical's operating margin?

Concord Medical (CCM) had an operating margin of -56.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Concord Medical's net profit margin?

Concord Medical (CCM) had a net profit margin of -20.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Concord Medical's free cash flow?

Concord Medical (CCM) generated -$36.9M in free cash flow during fiscal year 2025. This represents a 50.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Concord Medical's operating cash flow?

Concord Medical (CCM) generated -$28.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Concord Medical's total assets?

Concord Medical (CCM) had $936.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Concord Medical's capital expenditures?

Concord Medical (CCM) invested $8.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Does Concord Medical buy back shares?

Yes, Concord Medical (CCM) spent $20.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Concord Medical have outstanding?

Concord Medical (CCM) had 130M shares outstanding as of fiscal year 2025.

What is Concord Medical's current ratio?

Concord Medical (CCM) had a current ratio of 0.48 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Concord Medical's debt-to-equity ratio?

Concord Medical (CCM) had a debt-to-equity ratio of -1.17 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Concord Medical's return on assets (ROA)?

Concord Medical (CCM) had a return on assets of -1.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Concord Medical's cash runway?

Based on fiscal year 2025 data, Concord Medical (CCM) had $42.6M in cash against an annual operating cash burn of $28.9M. This gives an estimated cash runway of approximately 18 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Concord Medical's debt-to-equity ratio negative or unusual?

Concord Medical (CCM) has negative shareholder equity of -$300.7M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Concord Medical's Piotroski F-Score?

Concord Medical (CCM) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Concord Medical's earnings high quality?

Concord Medical (CCM) has an earnings quality ratio of 2.17x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Concord Medical cover its interest payments?

Concord Medical (CCM) has an interest coverage ratio of -1.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Concord Medical?

Concord Medical (CCM) scores 17 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.